Prime Medicine, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
PRME$4.30-7.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets F-
| December 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2025 | 2024 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $63,032 | $182,476 |
| Short-term investments | 114,648 | 2,998 |
| Short-term investment — related party | — | 4,968 |
| Prepaid expenses | 2,939 | 6,777 |
| Other current assets | 674 | 14,667 |
| Total current assets | 181,293 | 211,886 |
| Property and equipment, net | 20,572 | 24,404 |
| Operating lease right-of-use assets | 126,177 | 47,156 |
| Restricted cash | 13,691 | 14,062 |
| Other assets | 1,000 | — |
| Total assets | $342,733 | $297,508 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,887 | $11,351 |
| Accrued expenses and other current liabilities | 12,600 | 15,904 |
| Deferred revenue — related party | 7,824 | 7,092 |
| Operating lease liability | 8,137 | 3,614 |
| Total current liabilities | 37,448 | 37,961 |
| Deferred revenue, net of current — related party | 58,127 | 63,218 |
| Operating lease liability, net of current | 108,290 | 37,180 |
| Research and development funding liability | 18,000 | 6,000 |
| Total liabilities | 221,865 | 144,359 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity | ||
| Common stock, par value of $0.00001 per share; 775,000,000 shares authorized; 180,514,014 and 131,160,842 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 2 | 2 |
| Additional paid-in capital | 1,009,138 | 840,358 |
| Accumulated other comprehensive income | 82 | 1 |
| Accumulated deficit | (888,354) | (687,212) |
| Total stockholders’ equity | 120,868 | 153,149 |
| Total liabilities and stockholders’ equity | $342,733 | $297,508 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.